, the reaction product of the interaction between superoxide (O 2 ⅐ Ϫ ) and nitric oxide (⅐NO), is a potent proinflammatory nitroxide implicated in acute and chronic inflammatory conditions of many etiologies (1-4). Tissue injury and inflammation often accompany rapid development of hypersensitivities to noxious and nonnoxious stimuli (hyperalgesia and allodynia, respectively). Both peripheral mechanisms at the site of injury and central processes, particularly in the spinal cord, contribute to this phenomenon (5) via the release of nitrooxidative species. Specifically, ⅐NO, O 2 ⅐ Ϫ and ONOO Ϫ , in addition to cyclooxygenase (COX
), the reaction product of the interaction between superoxide (O 2 ⅐ Ϫ ) and nitric oxide (⅐NO), is a potent proinflammatory nitroxide implicated in acute and chronic inflammatory conditions of many etiologies (1) (2) (3) (4) . Tissue injury and inflammation often accompany rapid development of hypersensitivities to noxious and nonnoxious stimuli (hyperalgesia and allodynia, respectively). Both peripheral mechanisms at the site of injury and central processes, particularly in the spinal cord, contribute to this phenomenon (5) via the release of nitrooxidative species. Specifically, ⅐NO, O 2 ⅐ Ϫ and ONOO Ϫ , in addition to cyclooxygenase (COX)-derived prostaglandins (PGs), play an important role in the development of such peripheral and central sensitization (6, 7) . We recently reported that O 2 ⅐ Ϫ , in addition to its wellestablished role of O 2 ⅐ Ϫ in inflammation, is also involved in hyperalgesia. Notably, the direct intraplantar injection of O 2 ⅐ Ϫ in rats evokes potent thermal hyperalgesia (8) . Its removal with superoxide dismutase mimetics (SODm) blocks hyperalgesia associated with inflammation (8, 9) or following chronic morphine administration (morphine induced antinociceptive tolerance) (10) , and in response to spinal activation of the N-methyl-d-aspartate (NMDA) receptor (11) . Although the relative contributions of ONOO Ϫ to hyperalgesia are incompletely understood, abrogation of its biological activity with ONOO Ϫ decomposition catalysts such FeTM-4-PyP 5ϩ (Fe(III)5,10,15,20-tetrakis(N-methylpyridinium-4-yl)porphyrin) (4, 12) inhibited the development of morphine-induced hyperalgesia and antinociceptive tolerance (10, 13) .
One potential molecular pathway by which nitrooxidative stress (herein defined as stress caused by the presence of O 2 ⅐ Ϫ , ⅐NO, and ONOO Ϫ ) may influence inflammatory events associated with the development of altered pain sensitivity is through modulation of cyclooxygenase (COX) enzymes (14, 15) . As originally reported by our group (16) and subsequently extended by others (15, 17, 18) , the COX enzymes (constitutive COX-1 and inducible COX-2) are "receptor targets" for the multifaceted action of ⅐NO and as such are regulated in its presence. Although the mechanisms by which ⅐NO activates COX enzymes remain undefined, we now know that ONOO Ϫ is involved in this activation through the oxidative inactivation or modification of key amino acids residues in the COX polypetide backbone (19, 20) . Other possibilities in this complex reaction biochemistry have been raised and discussed in detail (21) . Furthermore, nitrooxidative species activate transcription factors such as AP-1 and NF-B, as well as mitogen-activated protein kinases (MAPKs) such as p38 MAP kinase, which is known to induce COX-2 protein expression during inflammation (22) (23) (24) (25) . Substantial evidence supports the conclusion that the activation or induction of COX enzymes by nitrooxidative stress augments the production of proinflammatory and pronociceptive prostaglandin E 2 (PGE 2 ) at sites of inflammation (15, 16) . Because O 2 ⅐ Ϫ and ⅐NO are often coproduced during tissue injury and inflammation, we hypothesized that ONOO Ϫ formed by their interaction is the likely key determinant of hyperalgesia driven by nitrooxidative stress.
Accordingly, the goals of our study were 1) to determine whether ONOO Ϫ is a hyperalgesic mediator; and 2) if so, to determine whether it acts through the COX-to-PGE 2 pathway. Results of this study support the proposition that therapeutic manipulations of ONOO Ϫ and its downstream consequences are mechanistically grounded targets for the development of novel nonnarcotic analgesics. In light of the synergism shown herein between the nonsteroidal anti-inflammatory drugs (NSAIDs) indomethacin and NS398 in relation to FeTM-4-PyP 5ϩ , our results suggest that combining NSAIDs and ONOO Ϫ decomposition catalysts may provide an improved therapeutic strategy to NSAIDs alone for inflammatory pain management.
MATERIALS AND METHODS

Animals
Sprague-Dawley rats (male, 175-200 g; Harlan, Indianapolis IN, USA) were used throughout these studies and housed and cared for using protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the Saint Louis University Medical Center and were in accordance with the U.S. National Institutes of Health Guidelines on Laboratory Animal Welfare. Animal use at the University of Messina was likewise in compliance with Italian regulations on the protection of animals used for experimental and other scientific purposes (D.M. 116192) as well as with European Economic Community regulations.
Drug administration
All drugs were given by intraperitoneal injection (1 ml/kg) 30 min before intraplantar injection of O 2 ⅐ Ϫ , ONOO Ϫ , or carrageenan. The PGE 2 monoclonal antibody (lyophilized powder EIA; Cayman Chemicals, Milan, Italy) was given by intraperitoneal injection at 200 g/kg, 18 h prior to intraplantar injection of PGE 2 , as described previously (26) . FeTM-4-PyP 5ϩ was purchased from Alexis (Milan, Italy) and NS398 [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide] from Cayman Chemicals. Decomposed superoxide was prepared using a dimethyl sulfoxide solution of potassium superoxide exposed to air for 30 min, and decomposed peroxynitrite was purchased from Upstate. All other drugs were purchased from Sigma (St. Louis, MO, USA Ϫ or ONOO Ϫ , respectively, in a total volume of 50 l) or carrageenan (0.1 ml of a 1% suspension in 0.85% NaCl) into the right hindpaw. Hyperalgesic responses to heat were determined at specified time points as described by Hargreaves (27) ; a cutoff latency of 20 s was used to prevent tissue damage. Rats were individually confined to plexiglass chambers. A mobile unit consisting of a high-intensity projector bulb was positioned to deliver a thermal stimulus directly to an individual hindpaw from beneath the chamber. The withdrawal latency period of injected and contralateral paws was determined to the nearest 0.1 s with an electronic clock circuit and thermocouple. Each point represented the change (s) in withdrawal latency (calculated from the withdrawal latency of the contralateral paw minus the withdrawal latency of the injected paw) at each time point. Results are expressed as Paw-withdrawal latency change (s). Development of paw edema was assessed by measuring paw-volume changes before and after O 2 ⅐ Ϫ , ONOO Ϫ , or carrageenan with a plethysmometer (Ugo-Basile, Varese, Italy) as described previously (28) . Results are expressed as Paw-volume change (ml).
Determination of PGE 2 release in carrageenan-injected rat paws PGE 2 released in the paw exudates was measured as described previously (28) . Briefly, at 6 h following the intraplantar injection of carrageenan, rats in each group were sacrificed, and each paw was excised at the level of the calcaneus bone. Paws were gently centrifuged at 250 g for 20 min to recover a sample of the edematous fluid, and the volume of fluid recovered from each paw was measured. PGE 2 levels were measured by ELISA using commercially available kits (Cayman), and results were expressed in pg/paw, normalizing values to the amount of exudate recovered from each paw. All determinations were performed in duplicate.
Western blot analysis for IB-␣, the p65 subunit of NF-B, COX-1, and COX-2 Cytosolic and nuclear extracts were prepared as described previously (29) , with slight modifications. Briefly, paw tissues from each rat were suspended in extraction buffer A, containing 0.2 mM PMSF, 0.15 M pepstatin A, 20 M leupeptin, and 1 mM sodium orthovanadate, homogenized at the highest setting for 2 min, and centrifuged at 1000 g for 10 min at 4°C. Supernatants represented the cytosolic fraction. The pellets, containing enriched nuclei, were resuspended in buffer B, containing 1% Triton X-100, 150 mM NaCl, 10 mM TRIS-HCl (pH 7.4), 1 mM EGTA, 1 mM EDTA, 0.2 mM PMSF, 20 m leupeptin, and 0.2 mM sodium orthovanadate. After centrifugation at 15,000 g for 30 min at 4°C, the supernatants containing the nuclear protein were stored at -80°C for further analysis. The levels of IB-␣, COX-1, and COX-2 were quantified in the cytosolic fraction from paw tissue collected 60 min after O 2 ⅐ Ϫ administration; levels of the NF-B subunit p65 were quantified in the nuclear fraction. The filters were blocked with 1ϫ PBS containing 5% (w/v) nonfat dried milk (PM) for 40 min at room temperature and subsequently probed with specific antibodies to IB-␣ (1: 1000; Santa Cruz Biotechnology, Milan, Italy), anti-iNOS PBS, 5% w/v nonfat dried milk, and 0.1% Tween-20 (PMT) at 4°C overnight. Membranes were incubated with peroxidaseconjugated bovine anti-mouse immunoglobulin G (IgG) secondary antibody or peroxidase-conjugated goat anti-rabbit IgG (1:2000, Jackson ImmunoResearch, West Grove, PA, USA) for 1 h at room temperature. To ascertain that blots were loaded with equal amounts of total protein, they were also incubated in the presence of the antibody against ␣-tubulin protein (1:10,000; Sigma-Aldrich Corp., Milan Italy). The relative expression of the protein bands for IB-␣ (ϳ37 kDa), NF-B p65 (65 kDa), iNOS (ϳ130 kDa), eNOS (ϳ155 kDa), COX-2 (ϳ72 kDa), and COX-1 (ϳ70 kDa) was quantified by densitometric scanning of the X-ray films with an imaging densitometer (GS-700; Bio-Rad Laboratories, Milan, Italy) and a computer program (Molecular Analyst; IBM, Armonk, NY, USA), and standardized for densitometric analysis to ␣-tubulin levels.
Histological examination of the O 2 ⅐ ؊ -inflamed rat hindpaw
For histopathological examination, biopsies of paws were taken 60 min after intraplantar injection of O 2 ⅐ Ϫ . Tissue from the pads of rat hindpaws was removed with a scalpel. Tissue samples were fixed in 10% (w/v) PBS-buffered formaldehyde for 1 wk at room temperature, dehydrated by graded ethanol, and embedded in Paraplast (Sherwood Medical, Deland, FL, USA). Tissue sections (thickness 7 m) were deparaffinized with xylene, stained with hematoxylin/eosin, and studied using light microscopy (Leitz Dialux 22; Leica Microsystems, Wetzlar, Germany). All the histological studies were performed in a masked fashion.
Immunohistochemical localization of nitrotyrosine
Sixty minutes after intraplantar injection of O 2 ⅐ Ϫ , tissue localizations for the formation of nitrotyrosine, a specific marker of nitrosative stress, were measured by immunohistochemical analysis in the paw tissue sections. Briefly, the tissues were fixed in 10% (w/v) PBS-buffered formaldehyde, and 8 m sections were prepared from paraffin-embedded tissues. After deparaffinization, endogenous peroxidase was quenched with 0.3% (v/v) hydrogen peroxide in 60% (v/v) methanol for 30 min. The sections were permeabilized with 0.1% (w/v) Triton X-100 in PBS for 20 min. Nonspecific adsorption was minimized by incubating the section in 2% (v/v) normal goat serum in PBS for 20 min. Endogenous biotin or avidin binding sites were blocked by sequential incubation for 15 min with biotin and avidin (DBA, Milan, Italy), respectively. Sections were incubated overnight with anti-nitrotyrosine rabbit polyclonal antibody (Upstate, Lake Placid, NY, USA; 1:500 in PBS, v/v). Sections were washed with PBS and incubated with secondary antibody. Specific labeling was detected with a biotin-conjugated goat antirabbit IgG and avidin-biotin-peroxidase complex (DBA). To verify the binding specificity for nitrotyrosine, some sections were also incubated with only the primary antibody (no secondary) or with only the secondary antibody (no primary). In these situations, no positive staining was found in the sections, indicating that the immunoreactions were positive in all the experiments performed.
Statistical evaluation
All values in the figures and text are expressed as mean Ϯ se for groups of n animals. In the experiments involving histology or immunohistochemistry, the figures shown are representative of at least three experiments performed on different days. The results were analyzed by 1-way ANOVA followed by
RESULTS
Peroxynitrite is a potent hyperalgesic mediator
As reported in our previous studies (8) (Fig. 1) coincided with protein nitration in paw tissues (Fig. 2B, B1) and tissue damage and inflammation as evidenced histologically by edema and a marked inflammatory cell infiltration (Fig. 2E) . The hyperalgesic responses to O 2 ⅐ Ϫ were attenuated in a dose-dependent manner by pretreatment with the nonselective NOS inhibitor L-NAME (N G -nitro-l-arginine methyl ester; ref. 30) (3-30 mg/ kg, nϭ6), (Fig. 1) . Because ⅐NO reacts with O 2 ⅐ Ϫ at a diffusion-limited rate to form ONOO Ϫ (1), these results with L-NAME together with our previous findings with superoxide dismutase mimetics (8) suggest that ONOO Ϫ from these two reactive species is the common denominator in the molecular and biochemical pathways leading to O 2 ⅐ Ϫ -mediated hyperalgesia, a role confirmed by the well-characterized ONOO Ϫ -decomposition catalyst FeTM-4-PyP 5ϩ (4) . Like L-NAME, FeTM-4-PyP 5ϩ also inhibited O 2 ⅐-mediated hyperalgesia in a dose-dependent manner (3-30 mg/kg, nϭ6) (Fig. 1) . Furthermore, FeTM-4-PyP 5ϩ (30 mg/kg, nϭ6) blocked protein nitration as detected by immunohistochemistry (Fig. 2C) (Fig. 2F) . Because L-NAME is a nonselective NOS inhibitor, it is unclear whether the ONOO Ϫ is generated from O 2 ⅐ Ϫ interacting with ⅐NO derived from the constitutive or inducible NOS enzymes, or both; this interesting question was not part of the overall objectives of the present study. The role of ONOO Ϫ as a mediator of hyperalgesia was underscored by the finding that intraplantar injection of ONOO Ϫ (0.1-3 M, nϭ6) evoked a dose-dependent hyperalgesic response to noxious heat that peaked by 60 -90 min (Fig. 3A) . The time course of ONOO Ϫ -induced hyperalgesia was similar to that using O 2 ⅐ Ϫ (8). The dose-dependent development of ONOO Ϫ -induced hyperalgesia also was inhibited by FeTM-4-PyP 5ϩ (3-30 mg/kg, nϭ6; Fig. 3B ). The intraplantar injection of O 2 ⅐ Ϫ and ONOO Ϫ led to paw edema, which was also inhibited as anticipated by FeTM-4-PyP 5ϩ (not shown).
The COX-to-PGE 2 pathway plays a critical role in peroxynitrite-mediated hyperalgesia
Because the results obtained with ONOO Ϫ produced locally in paw tissues from endogenous ⅐NO and exog- (Fig.  4A, A1 ) and increased total NF-B p65 nuclear localization (Fig. 4B, B1 ). As shown in Fig. 5A , A1 and as reported by others (31, 32), a low basal level of COX-2 protein was detected in cytosolic extracts from tissues of vehicle-treated rats. Injection of ONOO Ϫ led to a significant increase in COX-2 protein accumulation (Fig. 5A, A1) . Notably, levels of constitutive COX-1 were not increased by ONOO Ϫ (Fig. 5B, B1) . The nonselective COX-1/COX-2 inhibitor, indomethacin (10 mg/ kg, nϭ6) or the more COX-2 selective inhibitor (33-35) NS398 (10 mg/kg, nϭ6) given intraperitoneally 30 min prior to the intraplantar injection of O 2 ⅐ Ϫ or ONOO Ϫ (1 M) partially but significantly reduced hyperalgesia (Fig. 6) . NS398 was used at doses previously shown to display in vivo selectivity for COX-2 vs. COX-1 (33) (34) (35) . Furthermore, as can be seen in Fig. 6 , intraperitoneal injection of an anti-PGE 2 antibody (200 g/kg) 18 h before the intraplantar injection of O 2 ⅐ Ϫ or ONOO Ϫ (1 M) blocked thermal hyperalgesia (Fig.  6 ). The anti-PGE 2 antibody was used at a dose previously shown to inhibit the development of carrageenanand PGE 2 -induced hyperalgesia (26) . These results suggest that hyperalgesic responses to ONOO Ϫ are mediated at least in part through COX-1 and COX-2 and that PGE 2 is an important signaling eicosanoid involved in this response.
The peroxynitrite decomposition catalyst FeTM-4-PyP 5؉ blocks carrageenan-induced hyperalgesia
Having established that ONOO Ϫ is a potent hyperalgesic mediator operating via the COX-to-PGE 2 pathway, we next extended and confirmed our findings in a well-established model of hyperalgesia associated with inflammation (27) . The development of thermal hyperalgesia and inflammation following the intraplantar injection of carrageenan is mediated by the production of O 2 ⅐ and ⅐NO (8, 28, 36) and COX-1-/COX-2-derived PGE 2 at peripheral and spinal sites (33, 35, (37) (38) (39) (40) (41) (Fig. 7A) , edema, and PGE 2 release 
Synergistic inhibition of carrageenan-induced hyperalgesia by combinations of COX inhibitors and ONOO ؊ decomposition catalysts
We next examined whether dual administration of an ONOO Ϫ decomposition catalyst and a COX inhibitor act in concert to additively block hyperalgesia. As reported by others (33) (34) (35) , intraperitoneal administration of NS398 (1-10 mg/kg, nϭ6) attenuated carrageenan-induced hyperalgesia and edema in a dosedependent manner (Fig. 8A, B) . The combination of a low dose of FeTM-4-PyP 5ϩ (3 mg/kg, nϭ6) and a low dose of NS398 (1 mg/kg, nϭ6) led to a significant attenuation of hyperalgesia and edema (Fig. 9A, B) , suggesting a synergistic interactions between these two pharmacological agents. Similar results were obtained with FeTM-4-PyP 5ϩ and indomethacin (not shown).
DISCUSSION
ONOO Ϫ is a well-established mediator of acute and chronic inflammation, but its role in nociception is not well understood. Here we show that ONOO Ϫ , as generated by the interaction between exogenously supplied O 2 ⅐ Ϫ and endogenous ⅐NO, or when provided by direct injection of ONOO Ϫ , led to the development of thermal hyperalgesia associated with inflammation. Moreover, both the nociceptive and inflammatory responses were blocked with FeTM-4-PyP 5ϩ . To better define the molecular pathways involved in ONOO Ϫ -induced hyperalgesia, we focused our initial efforts on the COX pathway because of its regulation by nitrooxidative stress (14, 15) . Even so, other pathways and mechanisms may also be involved, including the ability of ONOO Ϫ to release proinflammatory and pronociceptive cytokines such as TNF-␣, IL-1␤, and IL-6 (23, 24, (42) (43) (44) and to cause post-translational nitration and modification of key proteins involved in central and peripheral sensitization (8, 10, 11) . Still, inhibiting synthesis or release of PGE 2 , one of the most thoroughly studied hyperalgesic PGs, contributes to the antihyperalgesic action of NOS inhibitors and to the hyperalgesic action of nitric oxide donors, respectively. Indeed, attenuation of hyperalgesia during tissue injury with NOS inhibitors (45), or in iNOS-deficient mice (46) , has been associated with a profound attenuation of peripheral and spinal release of PGE 2 . Similarly, the hyperalgesia resulting from exogenous administration of nitric oxide donors such as nitroglycerin is mediated at least in part by release of PGs and is blocked by NSAIDs such as indomethacin and nimesulide (47) (48) (49) .
Our results identify the COX-to-PGE 2 pathway as a key determinant in the hyperalgesic responses of ONOO Ϫ . Thus, the hyperalgesic responses to ONOO Ϫ were inhibited by the nonselective COX-1 and COX-2 inhibitor indomethacin, by the selective COX-2 inhibitor NS398 (33) (34) (35) , and by an anti-PGE 2 antibody. When administered exogenously, PGE 2 causes mechanical hyperalgesia in humans and experimental animals (50 -54) and sensitizes primary afferent nociceptors (55) (56) (57) (58) . These pronociceptive effects of PGE 2 are mediated via adenyl cyclase-cAMP-protein kinase A, since agents that inhibit this kinase as well as those that inhibit adenyl cyclase attenuate PGE 2 -induced hyperalgesia (59 -61) . Moreover, inhibition of COX-1 and COX-2 elicits antihyperalgesic effects associated with reduction of PGE 2 formation (33, 39, 50, (62) (63) (64) (65) , and anti-PGE 2 antibodies block hyperalgesia associated with tissue damage and inflammation (26, 41) .
Our findings strongly support the notion that nitrooxidative stress can modulate the COX pathway through both enzymatic activation and enzymatic induction (14, 15) . The mechanisms by which ⅐NO activate COX enzymes remain undefined but involve ONOO Ϫ -mediated oxidative inactivation or modification of key amino acids residues in the polypetide backbone (19, 20) . In addition to effects on COX-2 enzyme activity, ⅐NO and ONOO Ϫ increase the production of PGs from macrophages by acting post-transcriptionally or translationally to increase COX-2 protein levels or to increase its mRNA stability, at least in part through O 2 ⅐ Ϫ and the p38 MAPK pathway (17, 18, 66 -69) . Furthermore, iNOS binds COX-2, and iNOSderived ⅐NO increases the catalytic activity of COX-2 through S-nitrosylation in a macrophage cell line (70) . In our study (Fig. 5) , ONOO Ϫ significantly increased COX-2 but not COX-1 expression in inflamed paw tissues. These findings confirm that nitrooxidative species, including O 2 ⅐ Ϫ and ONOO Ϫ , activate redox-sensitive transcription factors such as NF-B and AP-1 as well as MAPK kinases such as p38 kinase (22) (23) (24) (25) . Because the induction of COX-2 in inflammation is regulated in part through the NF-B pathway (25) , it is likely that ONOO Ϫ -induced activation of NF-B and subsequent induction of COX-2 contributes to hyperalgesia. In view of these considerations, we propose ( Fig. 10) that ONOO Ϫ -mediated thermal hyperalgesia is driven at least in part by 1) activation of COX-1 and COX-2 in tandem with NF-B induction of COX-2 in paw tissues, increasing in situ formation of PGE 2 ; and 2) facilitation of PGE 2 -induced peripheral sensitization, as ⅐NO facilitates cAMP-dependent PGE 2 -induced hyperalgesia (71) . Whether ONOO Ϫ is also involved in the development of tactile hyperalgesia remains to be established, as its direct intraplantar injection failed to elicit tactile hyperalgesia despite the presence of significant inflammation (72) . The drugs used in our study were given systemically, and paw tissue expression of COX and PGE 2 release from paw tissues were measured. Consequently, additional analyses are needed to unravel the relative contributions of both peripheral and central sensitization processes in the development of ONOO Ϫ -mediated hyperalgesia. We are currently undertaking these studies. As a final note, once formed, ONOO Ϫ is converted to several other species, such as nitrosoperoxycarbonate or its conjugate acid, peroxynitrous acid (73) . At this stage it is not possible to address the in vivo contribution of such downstream species derived from ONOO Ϫ in the overall development of thermal hyperalgesia, because the appropriate molecular, biochemical, and pharmacological tools are not yet available. These exciting questions will be addressed as these tools become available.
An important finding of this study was that the degrees of inhibition of hyperalgesia and edema obtained by combining suboptimal doses of FeTM-4-PyP 5ϩ and NS398 or FeTM-4-PyP 5ϩ and indomethacin were synergistic. Especially notable was that maximal inhibition of hyperalgesia could be achieved with combinations of FeTM-4-PyP 5ϩ and NS398 or FeTM-4-PyP 5ϩ and indomethacin at doses at least 10-fold lower than those needed to elicit maximal inhibition with these agents given individually. Besides its role in acute inflammatory pain shown in this study, it has been recently reported that neutrophil-derived ONOO Ϫ also contributes to hyperalgesia associated with chronic inflammation arthritis (74) . Collectively, these findings have broad implications. Data from the Centers for Disease Control and Prevention indicate over 40 million annual cases of inflammatory pain in the United States alone, and NSAIDs are the most commonly used class of analgesics for moderate to severe inflammatory pain. Indeed, selective inhibitors of COX-2 were designed to prevent the adverse effects of nonselective COX inhibitors while retaining their potent anti-inflammatory and pain-relieving actions (75) . Although this goal was reached to some extent (76, 77) , some COX-2 inhibitors increase the risk of thrombosis (77) . Our results suggest that ONOO Ϫ decomposition catalysts are useful as novel nonnarcotic analgesics for inflammatory pain, either as stand-alone therapeutic agents or as adjuncts to COX inhibitors. The latter combination paradigm may provide an alternative strategy for the safe and effective management of pain states currently limited by the side-effect profile of selective and nonselective COX inhibitors. Ϫ is a potent hyperalgesic nitrooxidative species acting, at least in part, via the activation of COX-1 and COX-2 and the induction of COX-2 through the NF-B pathway. Subsequent formation of PGE 2 is an essential component to the development of ONOO Ϫ hyperalgesia. Dual inhibition of ONOO Ϫ and COX activity may provide an alternative therapeutic approach to the management of pain: effective analgesia with reduced side -effects typically associated with the use of COX inhibitors.
